Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System

The results demonstrated that certain GVHD prophylaxis drug combinations, particularly those including cyclosporine, may be relatively ineffective. However, avoiding cyclosporine is not always feasible in clinical settings, where treatment plans must be tailored to each patient. To address this issue, the study also identified cyclosporine-containing drug combinations that exhibit high efficacy. These findings could help inform the development of personalized treatment strategies for GVHD prophylaxis and thus improve outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.